Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06566391 | Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma | unknown | Phase 2 | 35 | European Institute of OncologyOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT05229614 | Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease(ICONIC) | unknown | Phase 2 | 27 | CNAO National Center of Oncological HadrontherapyOTHER | 2 | Aug 21, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT06556004 | Phase 1 Study Using TRIMELVax for Stage IIIC / IV Melanoma Patients(Trimelvax001) | unknown | Phase 1 | 20 | University of ChileOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04951583 | Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma(FMT-LUMINATE) | unknown | Phase 2 | 45 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05013099 | Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies(iPREDICT) | unknown | Phase 2 | 70 | ImaginAb, Inc.INDUSTRY | 6 | Jul 22, 2024 | clinicaltrials |
| NCT04272658 | PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy(IMMUNOPET2) | unknown | — | 56 | University Hospital, BrestOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT06414343 | LATe TreatmENT Related Toxicity in Melanoma (LATENT)(LATENT) | unknown | — | 400 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05060432 | Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors(TIG-006) | unknown | Phase 1 / Phase 2 | 153 | iTeos Belgium SAINDUSTRY | 6 | Jun 21, 2024 | clinicaltrials |
| NCT06254196 | Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies(Telenursing) | unknown | N/A | 40 | Regina Elena Cancer InstituteOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT05075356 | iToBoS: Clinical Data Acquisition Study(iToBoS) | unknown | N/A | 600 | The University of QueenslandOTHER | 0 | May 14, 2024 | clinicaltrials |
| NCT05354102 | A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128 | unknown | Phase 1 | 11 | Biomica Ltd.INDUSTRY | 1 | May 7, 2024 | clinicaltrials |
| NCT04193956 | POINTING: Clinical Cohort Study of Patients With Melanoma and NSCLC Receiving Checkpoint Inhibitors(POINTING) | unknown | — | 3,500 | University Medical Center GroningenOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT06116461 | Nivolumab Dose Optimization in Patients With a Complete, Partial or Stable Response(NIVOPTIMIZE) | unknown | Phase 4 | 34 | Erasmus Medical CenterOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT05520294 | Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma | unknown | — | 90 | University of Colorado, DenverOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06321640 | Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.(POSITive) | unknown | — | 265 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06299878 | MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns](CRISTINA) | unknown | — | 72 | Russian Academy of Medical SciencesOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06280040 | Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma | unknown | — | 20 | Medical University of ViennaOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04879654 | Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery(SNMM) | unknown | Phase 2 | 45 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06294379 | Shared Decision Making in Melanoma Patients Receiving Adjuvant Therapy | unknown | — | 150 | Odense University HospitalOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT06284512 | Uveal Melanoma - Comparative Study | unknown | — | 50 | Medical University of ViennaOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06281912 | Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients(MELCAYA) | unknown | — | 70 | Azienda Ospedaliera di PerugiaOTHER | 7 | Feb 28, 2024 | clinicaltrials |
| NCT05135715 | A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) | unknown | Phase 2 | 50 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06254547 | Leaderboard Influence on Self-Regulated Training in a Gamified Dermoscopy Training App | unknown | N/A | 150 | Herlev HospitalOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT06239623 | ERK Inhibitor JSI-1187 in Advanced Solid Tumors | unknown | Phase 1 | 60 | JS InnoPharm, LLCINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06236360 | Metastatic Melanoma Patients on Immunotherapy With Nutritive Intervention Based on Mediterranean Diet(MINI-MD) | unknown | N/A | 30 | University Hospital RijekaOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03068624 | Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma | unknown | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT00368615 | Characterization of the Melanoma-Specific Immune Response(Melanoma) | unknown | — | 20 | University of California, DavisOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06207747 | Quantitative Analysis of PET/CT Images of Immune Related Side Effects in Metastatic Melanoma Patients | unknown | N/A | 70 | Institute of Oncology LjubljanaOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04720768 | Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE(CELEBRATE) | unknown | Phase 1 / Phase 2 | 78 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT02557321 | PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 50 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT02977052 | Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab(OpACIN-neo) | unknown | Phase 2 | 186 | The Netherlands Cancer InstituteOTHER | 4 | Nov 15, 2023 | clinicaltrials |
| NCT05094804 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | unknown | Phase 1 / Phase 2 | 172 | OncoResponse, Inc.INDUSTRY | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05370807 | A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma(RegoMel) | unknown | Phase 2 | 48 | Universitair Ziekenhuis BrusselOTHER | 1 | Oct 24, 2023 | clinicaltrials |
| NCT05466474 | PD-1 Antibody Tislelizumab Combined With Dacarbazine in the Treatment of Advanced Melanoma | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Oct 24, 2023 | clinicaltrials |
| NCT06080711 | AI-Augmented Skin Cancer Diagnosis in Teledermatoscopy(AIDMel) | unknown | N/A | 30 | Karolinska University HospitalOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06073548 | Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study(SALOME Quali) | unknown | — | 250 | Institut CurieOTHER | 0 | Oct 10, 2023 | clinicaltrials |
| NCT04546074 | Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma | unknown | Phase 1 / Phase 2 | 22 | Keio UniversityOTHER | 1 | Oct 3, 2023 | clinicaltrials |
| NCT01586767 | Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy | unknown | N/A | 45 | Massachusetts General HospitalOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04986696 | Irradiation of Melanoma in a Pulse(IMPulse) | unknown | N/A | 46 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05986331 | Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma | unknown | Phase 3 | 366 | BiocadINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06041724 | Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma | unknown | Phase 2 | 46 | Fudan UniversityOTHER | 0 | Sep 18, 2023 | clinicaltrials |
| NCT04799106 | Community Based Strategies for Early Detection of Melanoma | unknown | — | 200 | Cedars-Sinai Medical CenterOTHER | 0 | Aug 29, 2023 | clinicaltrials |
| NCT03808441 | CAcTUS - Circulating Tumour DNA Guided Switch(CAcTUS) | unknown | Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05990634 | LifeChamps Feasibility Study | unknown | N/A | 20 | Region StockholmOTHER_GOV | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05984108 | Clinical, Radiological, Histologic and Molecular Features of a Cohort of Melanocytic Tumors of the Central Nervous System(MelaMen) | unknown | — | 50 | Central Hospital, Nancy, FranceOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05739006 | Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | unknown | Phase 1 | 131 | BiocadINDUSTRY | 1 | Aug 2, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Oct 2, 2024source: clinicaltrials